3 Key Takeaways
Plain English Summary- 01Core Finding
For the primary efficacy (real-world effectiveness in the trial) endpoint, least-squares mean percentage changes in body weight at week 24 were -19.7% to -13.6% with UBT251 vs. -2.0% with placebo (inactive comparison treatment); placebo-adjusted differences were -17.7% (95% confidence interval [CI], -20.8% to -14.6%) to -11.5% (95% CI, -14.1% to -9.0%; all p < 0.001).
- 02Study Evidence
Tested in a randomized controlled trial + observational cohort study (205 adults) at the Phase III stage.
- 03Practical Meaning
Large Phase III clinical evidence — long-term durability and rare subgroup effects remain under study.
What This Means for You
UBT251 produced weight reduction with cardiometabolic improvements and an acceptable safety profile, supporting Phase 3 evaluation. This study was registered at China Drug Trials Registry (CTR20250288) and ClinicalTrials.gov (NCT07177469).
The Discovery
UBT251 is a novel triple agonist targeting glucagon-like peptide-1, glucose-dependent insulinotropic polypeptide, and glucagon receptors. In this multicenter, randomized, double-blind, placebo (inactive comparison treatment)-controlled Phase 2 trial, 205 adults with overweight or obesity (a clinically meaningful level women; aged 18-61 years; without type 2 diabetes) received once-weekly UBT251 at 2 mg, 4 mg (initial dose 0.5 mg or 1 mg), or 6 mg, or placebo for 24 weeks. For the primary efficacy (real-world effectiveness in the trial) endpoint, least-squares mean percentage changes in body weight at week 24 were -a clinically meaningful level to -a clinically meaningful level with UBT251 vs. -a clinically meaningful level with placebo; placebo-adjusted differences were -a clinically meaningful level (a clinically meaningful level confidence interval [CI], -a clinically meaningful level to -a clinically meaningful level) to -a clinically meaningful level (a clinically meaningful level CI, -a clinically meaningful level to -a clinically meaningful level; all p < 0.001). UBT251 improved waist circumference, body mass index, blood pressure, lipid profiles, and glycemic parameters. The most frequent adverse events were mild-to-moderate gastrointestinal symptoms.
How It Works, Simply
This endocrinology research focuses on GLP-1 hormone pathway · Receptor targeting. Researchers evaluated it using a randomized controlled trial + Observational cohort study (205 adults) at the Phase III stage of medical research.
3 Key Takeaways
Clinical Takeaways- 01Core Finding
For the primary efficacy endpoint, least-squares mean percentage changes in body weight at week 24 were -19.7% to -13.6% with UBT251 vs. -2.0% with placebo; placebo-adjusted differences were -17.7% (95% confidence interval [CI], -20.8% to -14.6%) to -11.5% (95% CI, -14.1% to -9.0%; all p < 0.001).
- 02Study Evidence
Tested in a randomized controlled trial + observational cohort study (205 adults) at the Phase III stage.
- 03Practical Meaning
Large Phase III clinical evidence — long-term durability and rare subgroup effects remain under study.
Key Numbers
Biological Mechanism & Study Design
Study Design & Cohort
Randomized controlled trial + Observational cohort study
Randomized controlled trial + Observational cohort study (205 adults) · Phase III
Biological Pathway & Modality
GLP-1 hormone pathway · Receptor targeting
Intervention: UBT251, a novel triple GLP-1, GIP, and glucagon receptor agonist, in adults with
Experimental Findings & Endpoints
UBT251 is a novel triple agonist targeting glucagon-like peptide-1, glucose-dependent insulinotropic polypeptide, and glucagon receptors.
In this multicenter, randomized, double-blind, placebo-controlled Phase 2 trial, 205 adults with overweight or obesity (a clinically meaningful level women; aged 18-61 years; without type 2 diabetes) received once-weekly UBT251 at 2 mg, 4 mg (initial dose 0.5 mg or 1 mg), or 6 mg, or placebo for 24 weeks. For the primary efficacy endpoint, least-squares mean percentage changes in body weight at week 24 were -a clinically meaningful level to -a clinically meaningful level with UBT251 vs. -a clinically meaningful level with placebo; placebo-adjusted differences were -a clinically meaningful level (a clinically meaningful level confidence interval [CI], -a clinically meaningful level to -a clinically meaningful level) to -a clinically meaningful level (a clinically meaningful level CI, -a clinically meaningful level to -a clinically meaningful level; all p < 0.001).
UBT251 improved waist circumference, body mass index, blood pressure, lipid profiles, and glycemic parameters. The most frequent adverse events were mild-to-moderate gastrointestinal symptoms.
Clinical Translation & Practice Context
UBT251 produced weight reduction with cardiometabolic improvements and an acceptable safety profile, supporting Phase 3 evaluation.
This study was registered at China Drug Trials Registry (CTR20250288) and ClinicalTrials.gov (NCT07177469).
The Bottom Line · Clinical Pearl
“This study was registered at China Drug Trials Registry (CTR20250288) and ClinicalTrials.gov (NCT07177469).”
Published in Cell Metabolism · Current Stage: Phase III